Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03071224 · ClinicalTrials.gov registry record · Early Phase 1

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

A Early Phase 1 study of Alzheimer Disease and Healthy Volunteers, sponsored by Invicro.

Completed
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT03071224 is a Early Phase 1 study of Alzheimer Disease and Healthy Volunteers that has completed, run by Invicro. The registered enrollment target is 10 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03071224, a Early Phase 1 study of Alzheimer Disease and Healthy Volunteers, has completed, sponsored by Invicro.

COMPLETED
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.

Conditions Studied

Alzheimer Disease Healthy Volunteers

Interventions

  • DRUG [18F] MNI-946
  • DRUG [18F]Florbetapir

Study Locations (1)

Connecticut

  • Invicro - New Haven

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-06
Est. Completion 2021-06-09
Phase Early Phase 1

Sponsor

Invicro

14 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03071224

The ClinicalTrials.gov registry entry for NCT03071224 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which [18F] MNI-946 is the first listed.

NCT03071224 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03071224 about?

NCT03071224 is a clinical study titled "Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein". The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.

What is the current status of trial NCT03071224?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2016-06. Estimated completion is 2021-06-09.

What conditions does trial NCT03071224 study?

This clinical trial studies the following conditions: Alzheimer Disease, Healthy Volunteers.

What interventions are being tested in trial NCT03071224?

The interventions under investigation include: [18F] MNI-946 (DRUG), [18F]Florbetapir (DRUG).

Who is sponsoring clinical trial NCT03071224?

This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03071224 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Healthy Volunteers

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.